NCT00556348View on ClinicalTrials.gov

Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

November 30, 2008

Conditions
Age Related Macular Degeneration
Interventions
DRUG

bevacizumab

1.25mg

All Listed Sponsors
lead

Instituto de Olhos de Goiania

OTHER

NCT00556348 - Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter